Scotiabank began coverage on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) in a report released on Friday, ...

Shares of the company were up 5.2% in extended trading. The spray, sold under the brand name neffy, will be dosed at 1 ...

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of ARS Pharmaceuticals (NasdaqGM:SPRY) with a Sector ...

Scotiabank analyst Louise Chen initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $30 price target The firm says ...

Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ARS Pharmaceuticals (SPRY – Research Report) and ...

The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...

ARS Pharmaceuticals’ (Nasdaq: SPRY) shares closed up 3.4% at $10.87 yesterday, after the company announced that the US Food ...

Neffy 1 mg is the “first significant innovation” for epinephrine delivery in small children aged 4 years and up in over 35 ...

US FDA approves ARS Pharma’s neffy 1 mg to treat type I allergic reactions for paediatric patients weighing 15 to less than 30 kilograms: San Diego Friday, March 7, 2025, 09:00 ...

The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' nasal spray for severe allergic ...

(Reuters) -The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' nasal spray for severe allergic reactions in patients who weigh between 15 and 30 kilograms ...